Advertisement

U.S. markets open in 2 hours 27 minutes

S&P Futures
4,132.75
-9.00(-0.22%)
Dow Futures
32,784.00
-8.00(-0.02%)
Nasdaq Futures
13,111.50
-71.75(-0.54%)
Russell 2000 Futures
1,938.30
-2.80(-0.14%)
Crude Oil
91.45
+0.69(+0.76%)
Gold
1,807.40
+2.20(+0.12%)

Advertisement

Perrigo Company plc (PRGO)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

42.58

-0.40

(-0.93%)

At close: 04:00PM EDT

42.58

0.00

(0.00%)

After hours:

07:13PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Short-term KST

View all chart patterns

Performance Outlook

Previous Close	42.98
Open	43.05
Bid	0.00 x 1300
Ask	0.00 x 3100
Day's Range	42.51 - 43.59
52 Week Range	31.32 - 50.90
Volume	1,589,865
Avg. Volume	1,334,666

Market Cap	5.729B
Beta (5Y Monthly)	0.91
PE Ratio (TTM)	N/A
EPS (TTM)	-0.82
Earnings Date	Aug 09, 2022
Forward Dividend & Yield	1.04 (2.45%)
Ex-Dividend Date	Sep 01, 2022
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-61% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PRGO

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Perrigo Company plc
Analyst Report: Perrigo Company plcPerrigo is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company’s product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.
Rating
Fair Value
Economic Moat
2 months agoMorningstar

All

PR Newswire
PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS
Second Quarter 2022 Highlights:
Zacks
QuidelOrtho (QDEL) Q2 Earnings Miss Estimates
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.55% and 7.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Westport Innovations (WPRT) Reports Q2 Loss, Tops Revenue Estimates
  Zacks
- LivePerson (LPSN) Reports Q2 Loss, Misses Revenue Estimates
  Zacks
Insider Monkey
Here’s What Makes Perrigo (PRGO) a Great Investment Option
Sound Shore Fund, an investment management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. The Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) declined 13.45% and 13.41%, respectively, in the second quarter of 2022, trailing the Russell 1000 Value Index (Russell Value) which declined 12.21%. […]